[Form 4] Galectin Therapeutics Inc. Insider Trading Activity

Filing Impact

(Low)

Filing Sentiment

(Positive)

Form Type

4

Rhea-AI Filing Summary

Analyzing...

07/18/2025 - 10:38 AM

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Galectin Therapeutics Inc

NASDAQ:GALT

GALT Rankings

#6636 Ranked by Market Cap

N/A Ranked by Dividends

#18 Top Gainer

GALT Latest News

Jul 9, 2025

Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026

Jun 10, 2025

Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension

May 15, 2025

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update

May 12, 2025

Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress

Apr 15, 2025

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress

GALT Latest SEC Filings

Jul 9, 2025

[8-K] Galectin Therapeutics Inc. Reports Material Event

GALT Stock Data

Market Cap 155.06M

Float 43.70M

Insiders Ownership 31.13%

Institutions Ownership 16.26%

Short Percent 12.94%

Industry Biotechnology

Sector Pharmaceutical Preparations

Website Link

Country United States

City NORCROSS